Literature DB >> 29124662

Dopamine agonist withdrawal in hyperprolactinemia: when and how.

Roberto Salvatori1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29124662     DOI： 10.1007/s12020-017-1469-0

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  14 in total

1.  Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

Authors:  Felipe F Casanueva; Mark E Molitch; Janet A Schlechte; Roger Abs; Vivien Bonert; Marcello D Bronstein; Thierry Brue; Paolo Cappabianca; Annamaria Colao; Rudolf Fahlbusch; Hugo Fideleff; Moshe Hadani; Paul Kelly; David Kleinberg; Edward Laws; Josef Marek; Maurice Scanlon; Luis G Sobrinho; John A H Wass; Andrea Giustina
Journal:  Clin Endocrinol (Oxf)       Date:  2006-08       Impact factor: 3.478

2.  Dopamine agonists and the risk of cardiac-valve regurgitation.

Authors:  René Schade; Frank Andersohn; Samy Suissa; Wilhelm Haverkamp; Edeltraut Garbe
Journal:  N Engl J Med       Date:  2007-01-04       Impact factor: 91.245

3.  Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

Authors:  Renzo Zanettini; Angelo Antonini; Gemma Gatto; Rosa Gentile; Silvana Tesei; Gianni Pezzoli
Journal:  N Engl J Med       Date:  2007-01-04       Impact factor: 91.245

4.  Second attempt to withdraw cabergoline in prolactinomas: a pilot study.

Authors:  Ratchaneewan Kwancharoen; Renata Simona Auriemma; Gayane Yenokyan; Gary S Wand; Annamaria Colao; Roberto Salvatori
Journal:  Pituitary       Date:  2014-10       Impact factor: 4.107

Review 5.  Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis.

Authors:  Miao Yun Xia; Xiao Hui Lou; Shao Jian Lin; Zhe Bao Wu
Journal:  Endocrine       Date:  2017-10-17       Impact factor: 3.633

Review 6.  Cabergoline use for pituitary tumors and valvular disorders.

Authors:  Renata S Auriemma; Rosario Pivonello; Lucia Ferreri; Prisco Priscitelli; Annamaria Colao
Journal:  Endocrinol Metab Clin North Am       Date:  2014-11-04       Impact factor: 4.741

Review 7.  Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis.

Authors:  Olaf M Dekkers; Joep Lagro; Pia Burman; Jens Otto Jørgensen; Johannes A Romijn; Alberto M Pereira
Journal:  J Clin Endocrinol Metab       Date:  2009-10-30       Impact factor: 5.958

8.  A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.

Authors:  J Webster; G Piscitelli; A Polli; C I Ferrari; I Ismail; M F Scanlon
Journal:  N Engl J Med       Date:  1994-10-06       Impact factor: 91.245

9.  Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.

Authors:  Annamaria Colao; Antonella Di Sarno; Paolo Cappabianca; Carolina Di Somma; Rosario Pivonello; Gaetano Lombardi
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

10.  Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile?

Authors:  Lucio Vilar; José Luciano Albuquerque; Patrícia Sampaio Gadelha; Frederico Rangel Filho; Aline Maria C Siqueira; Maíra Melo da Fonseca; Karoline Frazão Viana; Barbara Sales Gomes; Ruy Lyra
Journal:  Front Endocrinol (Lausanne)       Date:  2015-02-04       Impact factor: 5.555
View more
  1 in total

1.  Bu-Shen-Zhu-Yun decoction induces PRLR deubiquitination and JAK2/STAT5 activation via CSN5 in vitro.

Authors:  Hua Feng; Huifang Zhou; Jianxia Lu; Qing Zhang; Xingran Tang; Yujie Shang
Journal:  Aging (Albany NY)       Date:  2021-08-23       Impact factor: 5.682
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.